TrialThe Journal of infectious diseases2018

Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.

Rory D de Vries et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.